NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6100.50 139.50 (2.34%)

32.17% Gain from 52W Low

399.7K NSE+BSE Volume

NSE 13 Aug, 2025 3:31 PM (IST)

161,949.1

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

07 Aug 2025

6100.50

2.34%

Divi's Laboratories (DIVI IN) Q1FY26 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q1FY26 EBITDA was 4% below our estimates led by lower margins despite higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates stand marginally reduced by 3-4%. We expect 20% EBITDA CAGR and 12% PAT CAGR over FY25-27E. At CMP,...

Divi's Laboratories .. has an average target of 6447.40 from 5 brokers.

Divi's Laboratories Ltd.

19 May 2025

6100.50

2.34%

Divi's Laboratories (DIVI IN) Q4FY25 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY25 EBITDA beat our estimates led by higher gross margin (62%; up 200 bps QoQ). We expect GMs to sustain, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates broadly remain unchanged. We expect 22% EBITDA CAGR and 15% PAT CAGR over FY25-27E. At CMP, stock is trading at...

Divi's Laboratories Ltd. is trading above its 200 day SMA of 6099.3

Divi's Laboratories Ltd.

25 Mar 2025

6100.50

2.34%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Target

Geojit BNP Paribas

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Divi's Laboratories Ltd.

04 Feb 2025

6100.50

2.34%

DIVI'S LABORATORIES

Accumulate: Divi's Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Divi's Laboratories .. has an average target of 6447.40 from 5 brokers.

Divi's Laboratories Ltd.

03 Feb 2025

6100.50

2.34%

Custom synthesis drives earnings; generics stable QoQ

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Laboratories (DIVI) delivered in-line revenue. However, it reported better-than-expected EBITDA/PAT led by a better product mix and lower tax rate (due to the shift to a new tax regime).

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6579.4

Divi's Laboratories Ltd.

03 Feb 2025

6100.50

2.34%

Divis Labs (HOLD): Back to higher growth trajectory

Hold: Divi's Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q3 sales/EBITDA/PAT were 0.6%/7.5%/22.3% above our estimates. PAT was higher than estimated due to the adoption of the new tax regime

Divi's Laboratories .. has an average target of 6447.40 from 5 brokers.

Divi's Laboratories Ltd.

11 Nov 2024

6100.50

2.34%

Company set for continued growth

Buy: Divi's Laboratories Ltd.

Recommendation Target

Sharekhan

Divis Labs’ revenue for the quarter amounted to Rs. 2,238 crore, marking a 17% y-o-y increase and a 6% q-o-q rise, which was 4% above estimates.

Divi's Laboratories .. has an average target of 6447.40 from 5 brokers.

Divi's Laboratories Ltd.

10 Nov 2024

6100.50

2.34%

Divi's Labs (SELL): Healthy Q2; rich valuations

Sell: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

DIVI reported healthy 2QFY25 earnings which was a beat on our estimates. Exports contributed 87% of sales and the US 71%

Divi's Laboratories Ltd. is trading below its 30 day SMA of 6579.4

Divi's Laboratories Ltd.

05 Aug 2024

6100.50

2.34%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Target

ICICI Direct

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Divi's Laboratories Ltd.

04 Aug 2024

6100.50

2.34%

Generic business disappoints; valuations a tad pricey

Sell: Divi's Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Divi’s Laboratories’ (Divi’s) Q1FY25 result was sub-par. Revenue traction was driven by custom synthesis (CS) (up ~46% YoY), while generics grew 1.5% YoY due to double-digit price erosion in key products like Naproxen, Gabapentin and Dexamethasone.

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Is Divi's Laboratories Ltd. worth buying?

750 Votes:

Buy 78.0%

Sell 15.07%

Hold 6.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf